Fiegl et al. measured RASSF1A DNA methylation of extracellular DNA in the serum to monitor response of women with breast cancer and presence of RASSF1A methylation 1 year after primary surgery was evaluated as an independent predictor of poor outcome in these patients [18]. This evidence concerns the gene RASSF1 and breast cancer.